Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18048378 | 0.85 | TSHR (0.30) | TSHRNLRP3 | |
| SCHEMBL19445479 | 0.81 | — | — | |
| SCHEMBL1976528 | 0.81 | — | — | |
| SCHEMBL3565320 | 0.81 | — | — | |
| SCHEMBL25192455 | 0.74 | — | — | |
| SCHEMBL30935741 | 0.72 | — | — | |
| SCHEMBL14189792 | 0.71 | CTSA (0.33) | TSHR | |
| SCHEMBL20581718 | 0.70 | — | — | |
| SCHEMBL20581719 | 0.70 | — | — | |
| SCHEMBL28992261 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5202090-A | — | — | None | — | — | JP | disclosed |
| US-20260132165-A1 | MODIFIED NUCLEOSIDE ANALOGUE AND USE THEREOF, AND NUCLEOSIDE ANALOGUE-CONTAINING DOUBLE-STRANDED OLIGONUCLEOTIDE AND USE THEREOF | RIGERNA THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2026-05-14 | — | — | US | disclosed |
| EP-4707392-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, CONJUGATE THEREOF, AND USE THEREOF | Rigerna Therapeutics (Beijing) Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-20250257356-A1 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| EP-4585603-A1 | GALNAC COMPOUND COMPRISING RIBOSE RING OR DERIVATIVE STRUCTURE THEREOF, AND OLIGONUCLEOTIDE CONJUGATE THEREOF | Hangzhou Tianlong Pharmaceutical Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| EP-4471144-A1 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024235124-A1 | MODIFIED NUCLEOSIDE ANALOGUE AND USE THEREOF, AND NUCLEOSIDE ANALOGUE-CONTAINING DOUBLE-STRANDED OLIGONUCLEOTIDE AND USE THEREOF | 北京炫景瑞医药科技有限公司 | 2024-11-21 | — | — | WO | disclosed |
| CN-118401539-A | Functionalized N-acetylgalactosamine analogues | 兆维生物科技公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118317970-A | Synthesis of 2' acetyl-ester protected nucleosides | 兆维生物科技公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-117866030-A | Cyclic dinucleotide compounds for the treatment of cancer | 卫材 R&D 管理有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20130137755-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | SEGEV LABORATORIES LIMITED (IL) | 2013-05-30 | — | — | US | disclosed |
| US-20110065909-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-7678542-B2 | Charge tags and the separation of nucleic acid molecules | THIRD WAVE TECHNOLOGIES, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090078574-A1 | CHARGE TAGS AND THE SEPARATION OF NUCLEIC ACID MOLECULES | THIRD WAVE TECHNOLOGIES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | KOSAK KENNETH M | 2008-02-28 | — | — | US | disclosed |
| WO-2007050789-A2 | GLYCOSYL-OLIGONUCLEOTIDE CONJUGATES AND METHODS | NËDKEN CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
| EP-1156054-B1 | DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-6495533-B1 | TUMOR NECROSIS FACTOR INHIBITORS; RHEUMATOID ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE, HEPATITIS, SEPSIS, HEMORRHAGIC SHOCK, MULTIPLE SCLEROSIS, CEREBRAL INFARCTION, DIABETES, INTERSTITIAL PNEUMONIA, PAIN, HIV | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1156054-A1 | DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-11-21 | — | — | EP | disclosed |
| JP-H05202090-A | NOVEL ANTISENSE OLIGONUCLEOTIDES HAVING PHOSPHORAMIDATE-CROSSLINKAGE AMONG NUCLEOTIDES THEREOF THROUGHOUT THE SAME | BAYER AG | 1993-08-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065909-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, CPSF1, CPSF6 | TSHR 1119/4885NLRP3 4621/4885 |
| US-20260132165-A1 | MODIFIED NUCLEOSIDE ANALOGUE AND USE THEREOF, AND NUCLEOSIDE ANALOGUE-CONTAINING DOUBLE-STRANDED OLIGONUCLEOTIDE AND USE THEREOF | NSUN2, TK1, SLC28A2 | TSHR 1898/4885NLRP3 4556/4885 |
| US-20250257356-A1 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | APOB, LPAR2, LPAR1 | TSHR 4091/4885NLRP3 4137/4885 |
| US-20130137755-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | NFATC1, KPNA2, KPNA6 | TSHR 1529/4885NLRP3 4659/4885 |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | CHMP4B, CTSA, CLTA | TSHR 4791/4885NLRP3 833/4885 |
| US-20090078574-A1 | CHARGE TAGS AND THE SEPARATION OF NUCLEIC ACID MOLECULES | NSUN2, NSUN3, NCL | TSHR 2375/4885NLRP3 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.